Browse the corpus

REFERENCES Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G-->A20210 gene variant. Ann Intern Med 1998; 129:89. Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol 2010; 85:947. Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999; 94:3388. Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8:37. Hirsh J. Heparin. N Engl J Med 1991; 324:1565. Fitches AC, Appleby R, Lane DA, et al. Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. Blood 1998; 92:4671. Bock SC, Harris JF, Balazs I, Trent JM. Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Genet 1985; 39:67. EGEBERG O. INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA. Thromb Diath Haemorrh 1965; 13:516. Marciniak E, Farley CH, DeSimone PA. Familial thrombosis due to antithrombin 3 deficiency. Blood 1974; 43:219. Carvalho A, Ellman L. Hereditary antithrombin III deficiency. Effect of antithrombin III deficiency on platelet function. Am J Med 1976; 61:179. Mackie M, Bennett B, Ogston D, Douglas AS. Familial thrombosis: inherited deficiency of antithrombin III. Br Med J 1978; 1:136. Bayston T, Lane D. Antithrombin mutation database, available at: www1.imperial.ac.uk/medicine/about/divisions/is/haemo/coag/antithrombin (Accessed on June 05, 2007). Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112:19. Ambruso DR, Leonard BD, Bies RD, et al. Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule. Blood 1982; 60:78. Odegård OR, Abildgaard U. Antithrombin III: critical review of assay methods. Significance of variations in health and disease. Haemostasis 1978; 7:127. Meade TW, Dyer S, Howarth DJ, et al. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1990; 74:77.

Ambruso DR, Leonard BD, Bies RD, et al. Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule. Blood 1982; 60:78. Odegård OR, Abildgaard U. Antithrombin III: critical review of assay methods. Significance of variations in health and disease. Haemostasis 1978; 7:127. Meade TW, Dyer S, Howarth DJ, et al. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1990; 74:77. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thromb Haemost 1992; 65:839. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87:106. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76:651. Brunel F, Duchange N, Fischer AM, et al. Antithrombin III Alger: a new case of Arg 47----Cys mutation. Am J Hematol 1987; 25:223. Ueyama H, Murakami T, Nishiguchi S, et al. Antithrombin III Kumamoto: identification of a point mutation and genotype analysis of the family. Thromb Haemost 1990; 63:231. Picard V, Dautzenberg MD, Villoutreix BO, et al. Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosis. Blood 2003; 102:919. Ambruso DR, Jacobson LJ, Hathaway WE. Inherited antithrombin III deficiency and cerebral thrombosis in a child. Pediatrics 1980; 65:125. Cosgriff TM, Bishop DT, Hershgold EJ, et al. Familial antithrombin III deficiency: its natural history, genetics, diagnosis and treatment. Medicine (Baltimore) 1983; 62:209. Bock SC, Harris JF, Schwartz CE, et al. Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene. Am J Hum Genet 1985; 37:32. Bock SC, Marrinan JA, Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry 1988; 27:6171. Sas G, Blaskó G, Bánhegyi D, et al. Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia. Thromb Diath Haemorrh 1974; 32:105. Olds RJ, Lane DA, Caso R, et al. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood 1992; 79:1206.

Sas G, Blaskó G, Bánhegyi D, et al. Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia. Thromb Diath Haemorrh 1974; 32:105. Olds RJ, Lane DA, Caso R, et al. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood 1992; 79:1206. Hultin MB, McKay J, Abildgaard U. Antithrombin Oslo: type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Thromb Haemost 1988; 59:468. Bock SC, Silberman JA, Wikoff W, et al. Identification of a threonine for alanine substitution at residue 404 of antithrombin III Oslo suggests integrity of the 404-407 region is important for maintaining normal plasma inhibitor levels. Thromb Haemost 1989; 62:494. Demers C, Ginsberg JS, Hirsh J, et al. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 1992; 116:754. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58:1094. Girolami A. The incidence of thrombotic manifestations in AT III abnormalities. Thromb Haemost 1987; 57:123. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. In: Clinics in Haematology, Prentice CR (Ed), Saunders, London 1981. Vol 10, p.369. Maung R, Kelly JK, Schneider MP, Poon MC. Mesenteric venous thrombosis due to antithrombin III deficiency. Arch Pathol Lab Med 1988; 112:37. Wilson C, Walker ID, Davidson JF, Imrie CW. Mesenteric venous thrombosis and antithrombin III deficiency. J Clin Pathol 1987; 40:906. Bertram B, Remky A, Arend O, et al. Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Ger J Ophthalmol 1995; 4:332. Ellis D. Recurrent renal vein thrombosis and renal failure associated with antithrombin-III deficiency. Pediatr Nephrol 1992; 6:131. Daif A, Awada A, al-Rajeh S, et al. Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke 1995; 26:1193. Das M, Carroll SF. Antithrombin III deficiency: an etiology of Budd-Chiari syndrome. Surgery 1985; 97:242. Candrina R, Goppini A, Salvi A, et al. Arterial thrombosis in antithrombin III deficiency. Clin Lab Haematol 1986; 8:267.

Daif A, Awada A, al-Rajeh S, et al. Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke 1995; 26:1193. Das M, Carroll SF. Antithrombin III deficiency: an etiology of Budd-Chiari syndrome. Surgery 1985; 97:242. Candrina R, Goppini A, Salvi A, et al. Arterial thrombosis in antithrombin III deficiency. Clin Lab Haematol 1986; 8:267. Heijboer H, Brandjes DP, Büller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323:1512. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353. Walker ID. Congenital thrombophilia. Baillieres Clin Obstet Gynaecol 1997; 11:431. Conard J, Horellou MH, Van Dreden P, et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63:319. Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68:589. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257:2162. Wunderwald P, Schrenk WJ, Port H. Antithrombin BM from human plasma: an antithrombin binding moderately to heparin. Thromb Res 1982; 25:177. Demers C, Henderson P, Blajchman MA, et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993; 69:231. Michiels JJ, Hamulyák K. Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost 1998; 24:309. Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2:581. McDonald MM, Hathaway WE, Reeve EB, Leonard BD. Biochemical and functional study of antithrombin III in newborn infants. Thromb Haemost 1982; 47:56. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70:165. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72:1651. Manco-Johnson MJ. Neonatal antithrombin III deficiency. Am J Med 1989; 87:49S.

Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70:165. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72:1651. Manco-Johnson MJ. Neonatal antithrombin III deficiency. Am J Med 1989; 87:49S. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248:6490. Downing MR, Bloom JW, Mann KG. Comparison of the inhibition of thrombin by three plasma protease inhibitors. Biochemistry 1978; 17:2649. Mitchell L, Piovella F, Ofosu F, Andrew M. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood 1991; 78:2299. Lechner K, Kyrle PA. Antithrombin III concentrates--are they clinically useful? Thromb Haemost 1995; 73:340. Büller HR, ten Cate JW. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med 1989; 87:44S. Damus PS, Wallace GA. Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy. Thromb Res 1975; 6:27. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24:19. Panicucci F, Sagripanti A, Conte B, et al. Antithrombin III, heparin cofactor and antifactor Xa in relation to age, sex and pathological condition. Haemostasis 1980; 9:297. Weenink GH, Kahlé LH, Lamping RJ, et al. Antithrombin III in oral contraceptive users and during normotensive pregnancy. Acta Obstet Gynecol Scand 1984; 63:57. Weenink GH, Treffers PE, Vijn P, et al. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity. Am J Obstet Gynecol 1984; 148:1092. Raya-Sánchez JM, González-Reimers E, Rodríguez-Martín JM, et al. Coagulation inhibitors in alcoholic liver cirrhosis. Alcohol 1998; 15:19. Segal H, Cottam S, Potter D, Hunt BJ. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997; 25:683.

Raya-Sánchez JM, González-Reimers E, Rodríguez-Martín JM, et al. Coagulation inhibitors in alcoholic liver cirrhosis. Alcohol 1998; 15:19. Segal H, Cottam S, Potter D, Hunt BJ. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997; 25:683. Pirisi M, Fabris C, Ceriello A, et al. Deficient antithrombin III activity and enhanced fibrinolysis in patients with liver disease: evidence against a cause-effect relationship. Acta Gastroenterol Belg 1995; 58:230. Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65:607. Chen TY, Huang CC, Tsao CJ. Hemostatic molecular markers in nephrotic syndrome. Am J Hematol 1993; 44:276. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68:392. Buchanan GR, Holtkamp CA. Reduced antithrombin III levels during L-asparaginase therapy. Med Pediatr Oncol 1980; 8:7. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90:235. Topic 1360 Version 4.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]